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Abstract
Schistosoma haematobium is the etiologic agent for urogenital schistosomiasis, a major source of morbidity and mortality
for more than 112 million people worldwide. Infection with S. haematobium results in a variety of immunopathologic
sequelae caused by parasite oviposition within the urinary tract, which drives inflammation, hematuria, fibrosis, bladder
dysfunction, and increased susceptibility to urothelial carcinoma. While humans readily develop urogenital schistosomiasis,
the lack of an experimentally-tractable model has greatly impaired our understanding of the mechanisms that underlie this
important disease. We have developed an improved mouse model of S. haematobium urinary tract infection that
recapitulates several aspects of human urogenital schistosomiasis. Following microinjection of purified S. haematobium
eggs into the bladder wall, mice consistently develop macrophage-rich granulomata that persist for at least 3 months and
pass eggs in their urine. Importantly, egg-injected mice also develop urinary tract fibrosis, bladder dysfunction, and various
urothelial changes morphologically reminiscent of human urogenital schistosomiasis. As expected, S. haematobium egg-
induced immune responses in the immediate microenvironment, draining lymph nodes, and systemic circulation are
associated with a Type 2-dominant inflammatory response, characterized by high levels of interleukin-4, eosinophils, and
IgE. Taken together, our novel mouse model may help facilitate a better understanding of the unique pathophysiological
mechanisms of epithelial dysfunction, tissue fibrosis, and oncogenesis associated with urogenital schistosomiasis.
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Introduction
Schistosomal infections plague more than 240 million people
worldwide. The most prevalent anthropophilic schistosome species
globally, Schistosoma haematobium, accounts for nearly half of that
number, primarily in sub-Saharan Africa and the Middle East [1].
S. haematobium infects humans through direct skin penetration by
aquatic cercariae that emerge from Bulinus truncatus, the interme-
diate snail host. After entering the human host, the parasite rapidly
migrates into the circulation as a schistosomulae, matures, and
subsequently lodges in the venous plexus of the bladder where
male-female worm pairs mate and produce eggs for years to
decades. While in rare cases ectopic S. haematobium oviposition
causes pathology outside of the urogenital tract, the vast majority
of infections result in urogenital schistosomiasis. Although the
symptoms are varied, the bulk of the morbidity and mortality of
urogenital schistosomiasis can be ultimately attributed to the host
immune response against Schistosoma eggs deposited within the
walls of the urinary tract. This inflammation leads to: 1)
compromise of urothelial integrity promoting urinary tract
infections [2–7], hematuria, and protein-wasting [2]; 2) urothelial
changes leading to carcinogenesis [8,9]; and 3) urinary tract
fibrosis causing bladder dysfunction, obstruction, infection, and
renal failure [10,11]. In fact, the annual death toll of 150,000 due
to urogenital schistosomiasis-induced obstructive renal failure
makes S. haematobium one of the most lethal worms worldwide
[12].
Despite the global burden of urogenital schistosomiasis, there
remains little known about the basic mechanisms underlying the
pathophysiologyofthis disease [13].Thisisprimarily duetothe lack
of an experimentally tractable animal model. Indeed, the majority
of research in schistosomiasis has focused on S. mansoni infections in
mice, wherein the entire life cycle can be recapitulated. In contrast,
the development of a mouse model of urogenital schistosomiasis,
long pursued by investigators in the field, has historically failed due
to the inability of S. haematobium cercariae to efficiently mature and
migrate to the bladder venous plexus in the mouse [14,15]. Thus, S.
haematobium research is largely limited to primate [16] and non-
murine rodent models [17,18]. Primate models, while capable of
faithful recapitulationofurogenital schistosomiasis,areprohibitively
expensive and difficult to manipulate. Extant non-murine rodent
models (e.g. hamster), in contrast, develop clinical outcomes which
can differ dramatically from the human disease. These models also
suffer from a paucity of species-specific tools.
PLoS Pathogens | www.plospathogens.org 1 March 2012 | Volume 8 | Issue 3 | e1002605Herein we report the development of a robust, highly
manipulable mouse model of urogenital schistosomiasis achieved
by the microinjection of viable S. haematobium eggs directly into the
bladder wall. This model faithfully and reproducibly recapitulates
some of the salient features of the human disease including
inflammatory cell activation and infiltration, urinary tract
granuloma formation and fibrosis, urinary dysfunction, systemic
Type 2 immune activation, and egg excretion in urine. To our
knowledge, this is the first experimentally tractable mouse model
of urogenital schistosomiasis. Moreover, we provide direct
evidence that egg deposition alone is sufficient to reproduce
several important aspects of urogenital schistosomiasis, even in the
absence of the other life stages of this important human pathogen.
Results
Intramural S. haematobium egg injection induces
reproducible granuloma formation and maturation
Although the morbidity associated with chronic S. haematobium
infection is considered to result from egg deposition into the
bladder wall, it is currently unclear whether oviposition alone, in
the absence of adult worms, is necessary and sufficient for the
bladder pathology associated with urogenital schistosomiasis. To
address this issue, we directly microinjected viable S. haematobium
eggs into the anterior bladder walls of female BALB/c mice. Serial
transabdominal micro-ultrasonography paired with histologic
verification demonstrated the development of injection site
granulomata over time (Figure 1A–H and Video S1). The initial
injection site response resolved entirely by day 4 in animals
injected with egg-free control vehicle (Figure 1E); whereas egg-
injected animals demonstrated a persistent mixed inflammatory
infiltrate (Figure 1F) with a hypoechoic appearance on micro-
ultrasonography (i.e., low density, grey mural nodules, Figure 1B).
Over the following 4 weeks, the egg-associated mixed inflamma-
tory infiltrate expanded and organized into a well-defined, egg-
centered granuloma surrounded by peripheral eosinophils and
neutrophils and containing distinct lymphoid follicles (Figure 1G).
Robust granulomata were still present 99 days after egg injection
(Figure 1H). These organized, dense lesions were correspondingly
hyperechogenic on micro-ultrasonography (bright nodules,
Figure 1D). Granuloma formation was neither sex- nor strain-
specific, since male and C57BL/6 and C3H/He mice also
developed granulomata after egg injection (unpublished data).
The granulomatous character of the egg-associated lesions was
confirmed by immunohistochemistry for CD68 (Figure 1I–K),
which demonstrated complete encapsulation of the eggs by CD68-
positive epithelioid cells (i.e., syncytial macrophages, Figure 1K).
Similar to human disease, granuloma development is accompa-
nied by eosinophiluria [19–24] and hematuria [25] (Figure S1).
Additionally, by post-injection day 4 the urothelium demonstrated
pronounced egg-dependent hyperplasia and squamous metaplasia
that persisted throughout the experimental time course (Figure 1L–
O and data not shown). These changes were present predomi-
nantly in the urothelium overlying the egg granuloma (Figure 1F–
H), suggesting a highly localized microenvironmental effect.
Importantly, these urothelial features closely parallel those
observed in urogenital schistosomiasis [26].
The observed pathology was not likely confounded by surgical
complications. In more than 100 consecutive injections performed
by four independent surgeons, no bladder perforation, extravesical
egg deposition, or significant post-injection sequelae were
observed. Micro-ultrasonographic and histologic analysis con-
firmed reproducible egg delivery to the same submucosal tissue
plane. Moreover, 20% of mice shed eggs in their urine within one
week of egg injection, which recapitulates egg shedding in infected
humans (data not shown).
Intramural S. haematobium egg injection induces bladder
fibrosis and urinary dysfunction
The host response to S. haematobium eggs in the human
urogenital tract involves a fibroproliferative response which is
thought to drive ureterovesical obstruction and bladder dysfunc-
tion, two major sources of morbidity associated with infection [27].
To determine whether our approach resulted in the development
of bladder fibrosis, we evaluated egg-injected bladders through
Masson’s Trichrome staining and total extractable collagen assays.
By day 7, loose immature collagen was observed within nascent
granuloma (Figure 2A). At day 28 post-injection, dense mature
collagen was found throughout the granuloma with variable
extension into the surrounding bladder tissue (Figure 2B). Control
vehicle-injected bladders demonstrated little or no collagen
staining (data not shown). In addition, total bladder soluble
collagen content was markedly increased 3–5 weeks post-egg
injection (Figure 2C). Finally, S. haematobium egg-injected mice
exhibited increased voiding frequency relative to control animals
(Figure 2D), which is consistent with reports of urinary frequency
observed in parasitized humans [28,29].
Egg-injected bladders accumulate an eosinophil- and
neutrophil-dominated mixed inflammatory infiltrate
The defined and synchronous nature of our egg injection model
allowed us to investigate the initial innate immune response to S.
haematobium egg deposition. Importantly, there was an immediate,
egg-independent upregulation of many cytokines in response to
the injection itself; however, this rapidly resolved over time
(Figures 3 and S2). Given that the foremost histologic hallmark of
human parasitic infection is eosinophil infiltration, it was expected
Author Summary
Urogenital schistosomiasis (infection with parasitic Schis-
tosoma haematobium worms, the most common human-
specific Schistosoma species globally) affects over 112
million people worldwide. S. haematobium worms primar-
ily lay eggs in the bladder, upper urinary and genital tracts,
and the host immune response to these eggs is considered
to cause almost all associated disease in these organs.
Resulting conditions include hematuria (bloody urine),
urinary frequency, fibrosis (internal scarring) of the urinary
tract, increased risk of bladder cancer, and enhanced
susceptibility to contracting HIV. Approximately 150,000
people die annually from S. haematobium-induced ob-
structive kidney failure alone, making this species one of
the deadliest worms worldwide. Despite the importance of
S. haematobium, a lack of an experimentally manipulable
model has contributed to the paucity of research focusing
on this parasite. We have circumvented the barriers to
natural S. haematobium oviposition in the mouse bladder
by directly microinjecting parasite eggs into the bladder
wall. This triggers inflammation, hematuria, urinary fre-
quency, fibrosis, egg shedding, and epithelial changes that
are similar to that seen in clinical S. haematobium
infections. Our model may provide new opportunities to
better understand the basic molecular and cellular
immunology of urogenital schistosomiasis and thereby
contribute to the development of new diagnostics and
therapeutics.
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upregulated relative to control-injected bladders (Figure 3A).
Consistent with the upregulation of eotaxin, we detected a large
number of eosinophils (Siglec-F
+ CCR3
+) that rapidly infiltrated
the injection site and persisted, whereas egg-free control vehicle
injections did not produce a significant response (Figure 4A, Figure
S1). In addition, there was a marked infiltration of neutrophils
(CD11b
+Gr-1
+) into the injected bladder wall with kinetics that
were similar to eosinophils (Figure 4B). This is consistent with the
egg-injected bladder upregulation of neutrophil-associated che-
mokines such as KC (CXCL1) [30] and MIP-1a (CCL3) [31]
(Figure 3). While B-cells (B220
+) also accumulated at the injection
site over time (Figure 4C), we noted a paucity of T cells (CD3
+),
though moderately elevated relative to egg-free controls
(Figure 4D). These data are consistent with histologic observations
(Figure 1F–H), and suggest that development of egg granulomata
in our model features B cell and chemokine-driven innate immune
cell infiltration with a relative dearth of T cells.
Figure 1. Bladder wall injection of S. haematobium eggs results in synchronous granuloma formation. Intramural injection of S.
haematobium eggs results in rapid and localized injection site response followed by progressive expansion and consolidation over several weeks
(serial micro-ultrasonography of a single representative animal, A–D; histology, E–H). Lymphoid follicles in H are marked with arrowheads. Scale bars
for panels E, I, J, and L (lower right hand corner for each) are 100 microns long. Immunohistochemical characterization demonstrates central
macrophage granuloma formation around injected eggs (arrows) with peripheral accumulation of other inflammatory cells (I–K, anti-CD68 brown).
Epithelioid cells (activated macrophages) are indicated with arrowheads. Egg injection also induces early and sustained urothelial hyperplasia with
reactive nuclear changes (L–O).
doi:10.1371/journal.ppat.1002605.g001
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biased microenvironment
S. mansoni and S. japonicum eggs elicit a dominant Type 2
immune response within mouse hosts. Despite the paucity of T
cells in our model, we sought to determine whether S. haematobium
eggs elicited the production of the canonical Type 2 cytokines IL-4
and IL-13. The Luminex multiplexed liquid microbead platform
was used to assay total cytokine expression within egg-injected
bladders at early time points that corresponded to the initial
immune response and nascent granuloma development (Figure 3
and Figure S2). IL-4 and IL-13 were upregulated by day 4 and
remained elevated throughout all time points examined
(Figure 3A). IL-5 levels were also markedly increased, which is
consistent with the role of this Type 2-associated cytokine in
eosinophil differentiation, activation, and recruitment [32] (Figure
S2). In contrast, TH1- and TH17-associated cytokines such as IFN-
c and IL-17 remained unaffected by the egg-induced inflamma-
tory response (Figure 3B–C). Consistent with the marked
neutrophil and macrophage infiltration of the egg-injected bladder
wall (Figures 1 and 3), the innate immunity-associated cytokines
TNF-a, KC, MCP-3, and MIP-1a demonstrated early and
sustained increases relative to controls (Figure 3A and 3D).
Interestingly, egg injection had no effect on IL-10 and TGF-b—
immunosuppressive cytokines associated with regulation of tissue
fibrosis in other diseases (Figure 3E).
Figure 2. S. haematobium egg-injected bladders develop fibrosis and urinary dysfunction. Egg-injected bladders demonstrate
histologically-apparent fibrosis within granulomata beginning at post-injection day 7 (A, Masson’s trichrome stain, collagen stains blue). Later time
points demonstrate increased collagen staining area and intensity (B). Total bladder soluble collagen content correlates with histologic evaluation
(C). Egg-injected mice demonstrate increased urinary frequency (1 week post injection, D).
doi:10.1371/journal.ppat.1002605.g002
A New Mouse Model of Schistosoma haematobium
PLoS Pathogens | www.plospathogens.org 4 March 2012 | Volume 8 | Issue 3 | e1002605Figure 3. S. haematobium egg-injected bladders demonstrate a local Type 2 immune response. Egg-injected bladders feature elevated
levels of the Type 2-associated cytokines IL-4, IL-13, and eotaxin (A) without significant changes in TH1- or TH17-associated cytokines (e.g. IFN-c [B]
and IL-17 [C], respectively). Cytokines and chemokines associated with innate immune activation (e.g. KC, TNF-a, MIP-1a, MCP-3, [D]) are persistently
elevated relative to control. The immunosuppressive cytokines IL-10 and TGF-b were not clearly differentially regulated in egg- versus control-
injected mice (E).
doi:10.1371/journal.ppat.1002605.g003
A New Mouse Model of Schistosoma haematobium
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in draining lymph nodes
Despite the relative paucity of T cells within the egg-injected
bladder (Figure 4D), the strikingly Type 2 cytokine-biased
microenvironment (Figure 3) supported a hypothesis that T helper
2 cells were likely to be involved in the immune response to S.
haematobium eggs. Indeed, pelvic lymph nodes draining egg-injected
bladders demonstrated marked upregulation of the TH2-associated
cytokine IL-4 throughout the experimental time course, while
expression of the TH1-associated cytokines IFN-c and IL-12 was
moderately altered due to the injection procedure (Figure 5).
Interestingly, at later time points the Treg-associated marker FoxP3
was markedly suppressed relative to controls while expression of
the immunosuppressive cytokines IL-10 and TGF-b was un-
changed. Expression of IL-17 was not detected.
Egg-injected mice display systemic Type 2-skewed
cytokine responses and IgE production
In our model, egg-injected mice demonstrated a reproducible,
systemic Type 2-biased immune response similar to that observed
in human infection. Serial multiplex serum cytokine profiling
demonstrated persistently elevated levels of the Type 2-associated
cytokine IL-5, while the TH1- and TH17-associated cytokines IFN-
c and IL-17, respectively, evinced no such increase (Figure 6A).
Congruent with chronic inflammation, the innate immunity-
associated cytokine IL-1a was also persistently elevated (Figure 6A).
Interestingly, serum levels of VEGF were increased in egg-injected
mice, which may have promoted aberrant vasculogenesis and
hematuria analogous to human disease [33]. Finally, serum levels
of IgE, a quintessential Type 2-associated antibody isotype, were
increased beginning at 14 days post egg injection relative to
controls, and remain elevated through day 28 post-injection
(Figure 6B).
Discussion
S. haematobium infection, i.e. urogenital schistosomiasis, lacks a
reliable mouse model despite being the most prevalent form of
schistosomiasis and one of the deadliest worm infections
worldwide. To address the lack of experimentally amenable tools
for investigation of this medically important pathogen, we have
developed an improved mouse model of urogenital schistosomi-
asis. Microinjection of viable S. haematobium eggs into the
submucosa of the bladder wall elicits pathology similar to certain
aspects of the human disease, including inflammatory cell
infiltration, granuloma formation, urinary tract fibrosis and
dysfunction, and systemic Type 2 immune activation. The focal
deposition of eggs and resulting composite granulomata observed
in this model recapitulates certain aspects of the immunopathology
observed in human disease [34–36]. The persistent granulomatous
inflammation in our model (at least 99 days after egg injection)
parallels the chronicity of human infection. Moreover, the
microinjection method features several advantages, including the
Figure 4. S. haematobium egg-injected bladders accumulate a mixed inflammatory infiltrate dominated by eosinophils and
neutrophils. Congruent with histologic evaluation, serial flow cytometric analyses of single cell suspensions made from egg-injected bladders
demonstrate progressive accumulation of (A) eosinophils (SiglecF
+CCR3
+), (B) neutrophils (CD11b
+Gr-1
+), (C) B cells (B220
+), and—to a lesser
extent— (D) T cells (CD3
+).
doi:10.1371/journal.ppat.1002605.g004
A New Mouse Model of Schistosoma haematobium
PLoS Pathogens | www.plospathogens.org 6 March 2012 | Volume 8 | Issue 3 | e1002605induction of anatomically precise, synchronous, and reproducible
pathology. Although microinjection of the bladder wall of a 20
gram mouse may appear daunting, proper magnification, clean
egg preparations, sharp injection needles, and careful surgical
technique render it feasible [37]. This is in contrast to existing
mouse models of percutaneous or intravenous S. haematobium
infection, which are prone to ectopic oviposition, variant kinetics,
and unreliable disease burden [14,15].
Current, non-mouse animal models for urogenital schistosomi-
asis mostly rely on non-human primates [16] and hamsters
[17,18]. Non-human primate models, while capable of high
fidelity recapitulation of human disease, are costly and difficult to
use. In hamsters transdermally infected with S. haematobium
cercariae, schistosomula reach the lung by 3 days post-infection,
followed by pairing of worms at approximately day 28–29.
Oviposition in hamster tissues, primarily lung, liver, intestine,
spleen, kidney, and uterus, begins to occur between weeks 7–11
[38–42]. Clustered egg deposition (often .20 eggs) results in giant,
composite granulomata in the hamster liver. In comparison, S.
mansoni infections of hamsters result in single egg-based liver
granulomata containing more eosinophils, fewer polymorphonu-
clear leukocytes and histiocytes [43,44]. Rates of hamster bladder
involvement after exposure to S. haematobium cercaria are low and
inconsistent, ranging from 0 to approximately 60%. Even when
bladder oviposition occurs, egg burdens tend to be much lighter
than that found in other organs, and less than two-thirds of
hamsters with bladder eggs feature urothelial hyperplasia or
squamous metaplasia [45]. Thus, hamsters develop clinical
pathology which can differ dramatically from human disease,
restricting their biological relevance. Hamsters also feature fewer
species-specific reagents than mice. Hence, our improved mouse
model of urogenital schistosomiasis may prove to be a useful
alternative to existing animal models of this disease.
In the course of characterizing our model we noted that
significant Type 2 inflammation occurs after egg injection, but this
is not accompanied by large numbers of granuloma-associated T
cells. Instead, we noted a rapid and pronounced chemokine
response ensued following egg inoculation. The rapidity of the
eotaxin response may indicate that eosinophils were recruited in
the absence of adaptive immunity, perhaps by the secretion of
eotaxin from urothelial, endothelial, smooth muscle, or other
resident cells that were likely in direct contact with the inoculum.
Certainly, urothelial cells can serve as a rapid source of
chemokines and other cytokines in response to exposure to
microbial antigens [46]. While the precise mechanism by which
eosinophils are initially recruited to the sites of Schistosoma infection
is not known, their later recruitment and accumulation is driven
by a local, robust Type 2-biased immune response [47]. Indeed
many of the aspects of parasitic morbidity, including those
associated with urogenital schistosomiasis, are driven by this
immune program. In humans, the parasite microenvironment has
been well-characterized in its later, chronic stages; however, the
early development and etiologic determinants of this immunologic
milieu are poorly understood, most especially in urogenital
schistosomiasis. The few T cells present in our model’s bladder
granulomata may be amplifying and organizing the local immune
response, given the development of lymphoid follicles late after egg
injection (Figure 1H). Despite the paucity of bladder-infiltrating T
Figure 5. S. haematobium egg-injected mice demonstrate Type 2 immune responses in draining lymph nodes. Pelvic lymph nodes from
egg-injected mice demonstrate persistently elevated expression of Type 2-associated cytokines (e.g. IL-4) without corresponding increases in theT H1-
associated cytokines IFN-c and IL-12. The TReg-associated marker FoxP3 is suppressed late in the experimental time course, while the
immunosuppressive cytokines IL-10 and TGF-b remain unchanged. IL-17 was not detected (N.D.).
doi:10.1371/journal.ppat.1002605.g005
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PLoS Pathogens | www.plospathogens.org 7 March 2012 | Volume 8 | Issue 3 | e1002605Figure 6. S. haematobium egg-injected mice display systemic Type 2 cytokine and immunoglobulin responses. Egg-injected mice
demonstrate elevated serum levels of Type 2-associated cytokines (e.g. IL-5) with decreased or unchanged serum levels of TH1- and TH17-associated
cytokines (e.g. IFN-c and IL-17, respectively, [A]). The Type 2 bias in systemic cytokine expression parallels increased IgE production (B).
doi:10.1371/journal.ppat.1002605.g006
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lymph nodes (Figure 5) argues in favor of regional activation of
TH2 cells. Alternatively, it is possible that basophils stimulated by
S. haematobium egg-derived IL-4 inducing principle from S. mansoni
eggs [48] (IPSE, originally known as S. mansoni chemokine binding
protein [smCKBP] [49]) subsequently transit through lymph
nodes and secrete IL-4 in these sites [50]. Other potential sources
of IL-4 include mast cells and natural killer T (NKT) cells, both of
which have been reported to localize to the lymph nodes [51,52].
The latter cellular subset has been specifically implicated in anti-
schistosomal immune responses [53]. Regardless of the source of
IL-4, IgE titers increased beginning two weeks after egg injection
(Figure 6B), providing consistent evidence for IL-4-dependent B
cell isotype switching [54].
Another important observation was the lack of differential
regulation of Th1 and Th17 cytokines (Figure 3). Immunologic
aspects of natural S. mansoni infections of mice feature early Th0 or
Th1 responses [55–57], with certain inbred mouse strains also
exhibiting a propensity for Th17-associated activity [58]. We
speculate that the differences between our model and this body of
work are due in part to the synchronous granuloma nature of our
approach, which does not include the cercarial-, schistosomular-,
and worm-triggered immune response. It is also possible that the
bladder immune microenvironment differs from other sites of
schistosomal infection, namely the lung, liver, and intestinal tract.
Further refinements to our model, and combination of our model
with natural infection models, will be necessary to dissect out these
important questions.
Besides differential cytokine expression, the systemic upregula-
tion of the growth factor VEGF in response to egg injection was
particularly striking (Figure 6A). Hematuria is a hallmark of
urogenital schistosomiasis, and by definition results when bladder
blood vessels and the urothelium break open and communicate
with the bladder lumen. We theorize that VEGF triggers
disorganized vasculogenesis and results in friable, easily disrupted
bladder neovasculature. Interestingly, cervicovaginal lesions asso-
ciated with urogenital schistosomiasis exhibit increased amounts of
sprouting blood vessels and granulation tissue, indicating a possible
role for VEGF and/or other vasculogenic influences [59].
The successful mimicry of several pathophysiologic facets of
urogenital schistosomiasis by direct egg microinjection suggests
that egg deposition alone may be sufficient to recapitulate some of
the salient aspects of human disease. We have preliminary
evidence that soluble S. haematobium egg antigens alone are also
capable of generating bladder inflammation (manuscript in
preparation). Use of genetically modified eggs in our model will
further define the molecular basis of bladder immunopathology
[60]. The observed long-term inflammation does not appear to be
caused by bacterial or endotoxin contamination of injection
solutions, since: 1) solutions are sterile; 2) endotoxin levels are
,0.06 EU/dose; and 3) injection of eggs or control vehicle does
not result in more TNF production than injection with low
endotoxin saline (data not shown).
The availability of an improved animal model of urogenital
schistosomiasis is of importance to multiple avenues of study.
Firstly, the ability to monitor and manipulate the disease in a host
(Mus musculus) for which numerous species-specific tools are
available enables experimental approaches which were previously
inaccessible. Secondly, the reliable reproduction of systemic and
urogenital stigmata in our model may allow identification and
evaluation of novel diagnostic and therapeutic strategies. Our use
of micro-ultrasound is, to our knowledge, the first reported
application of this technology for in vivo imaging of experimental
schistosomiasis. We have successfully employed mouse-specific
mass spectrometry and microarray analyses to profile S.
haematobium-induced host protein and gene expression signatures,
respectively (manuscripts in preparation). Egg-specific biomarker
studies are ongoing. These approaches have only been possible
through use of a mouse model featuring precisely controlled and
reproducible S. haematobium egg-induced immunopathology. Our
model may alleviate the bottleneck on urogenital schistosomiasis
research imposed by the scarcity and heterogeneity of infected
human samples, particularly bladder and lymphoid tissue.
When combined with other routes of egg injection or
transdermal infection with cercariae, our model of schistosome
egg-induced, Type 2-associated fibrosis is capable of synchronous
fibrosis in multiple anatomic sites including the bladder, liver, and
subcutis within the same animal (unpublished data). Cheever et al.
have demonstrated that sensitization of mice by adult S. mansoni
worm antigens enhances the egg-specific, lung immune response
[61]. Our model is amenable to testing analogous questions using
S. haematobium and the bladder. Through this strategy fibrosis in
different organ systems may be compared to identify shared and
organ-specific mechanisms and potential therapeutic targets. Prior
work by others has definitively demonstrated that schistosome egg-
induced lung, liver, and intestinal granuloma development is
greatly schistosome species-dependent, with differences among S.
haematobium, S. japonicum, S. mekongi, and S. mansoni [62,63]. In
addition, others have reported that hepatic- and lung-associated, S.
mansoni egg granulomata develop in a highly organ-specific fashion
[64]. S. japonicum granulomata also evolve in a tissue-specific
manner in the liver, lung, and intestinal tract [65]. These reports
highlight the critical need to develop in vivo models which properly
match schistosome species with their tropism for specific host
organs.
Additionally, our model of urogenital schistosomiasis presents a
unique opportunity to study schistosomiasis-associated carcino-
genesis [3,9], and potentially inflammatory carcinogenesis in
general (reviewed by Kuraishy et al. [66]). Urothelial carcinoma
associated with S. haematobium infection arises in a Type 2-biased
inflammatory environment. Approaches combining egg-induced
Type 2 immunopathology and inducible models of bladder
carcinogenesis represent new methods to study the role of
inflammatory bias in carcinogenesis.
Like all experimental models, our approach has limitations. The
injection procedure itself induces non-specific upregulation of a
number of cytokines at day 1 post-injection (Figures 4, 6, S2, and
S3). Use of uninfected hamster tissue homogenates as a control
‘‘vehicle’’ injection only partially mitigates this confounding issue.
Accordingly, the cytokine expression observed at day 1 post-
injection is likely the result of both parasite-specific and non-
specific stimuli. While local immune responses to eggs are directly
responsible for much of the observed pathology in S. haematobium
infection, this activity is part of a larger, systemic immune response
elicited in response to multiple life stages of the schistosome. In
human disease, S. haematobium infection proceeds through cercarial
skin invasion, systemic schistosomular circulation and maturation,
adult worm mating within the bladder venous plexus, and egg
deposition/excretion [67]. This complex natural history provides
potential exposure to a broad range of antigens; however, the
relative brevity of cercarial persistence and schistosomular
circulation (hours to days [68]) and the relative lack of antigenicity
of adult worms [69] may limit their contribution to long-term
immunopathology. The unexcreted schistosome egg, in contrast,
may persist for many years in host tissues and is a well-established,
potent immunogen (e.g., soluble egg antigen or SEA [69]). Indeed,
the systemic and granulomatous immune response to urogenital
schistosomiasis is primarily driven by egg-associated antigens
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granuloma formation induced by bolus injection of eggs into the
mouse tail, cecal, or portal vein [64,72,73]. Like other synchro-
nous granuloma models, our approach by definition is unsuitable
for the study of the cercarial, schistosomular, and worm stages of S.
haematobium.
In summary, we report the development of an improved mouse
model of urogenital schistosomiasis. The ease and robustness of
this model make it attractive for potential application to the
elucidation of disease mechanisms, discovery of novel diagnostic
biomarkers, and evaluation of candidate therapeutics. Addition-
ally, this model is a prospective platform for the study of basic
mechanisms of disease such as epithelial dysfunction, fibrosis, and
inflammatory carcinogenesis.
Materials and Methods
Ethics statement
All animal work has been conducted according to relevant U.S.
and international guidelines. Specifically, all experimental proce-
dures were carried out in accordance with the Administrative
Panel on Laboratory Animal Care (APLAC) protocol and the
institutional guidelines set by the Veterinary Service Center at
Stanford University (Animal Welfare Assurance A3213-01 and
USDA License 93-4R-00). Stanford APLAC and institutional
guidelines are in compliance with the U.S. Public Health Service
Policy on Humane Care and Use of Laboratory Animals. The
Stanford APLAC approved the animal protocol associated with
the work described in this publication.
Mice
7 to 8 week-old female BALB/c mice were purchased from
Jackson Laboratories. All experimental procedures were carried
out in accordance with the APLAC protocol and the institutional
guidelines set by the Veterinary Service Center at Stanford
University.
S. haematobium egg isolation
S. haematobium-infected LVG hamsters were obtained from the
National Institute of Allergy and Infectious Diseases Schistosomi-
asis Resource Center of the National Institutes of Health. The
hamsters were sacrificed at the point of maximal liver and
intestinal Schistosoma egg levels (18 weeks post-infection [74]), at
which time livers and intestines were minced, homogenized in a
Waring blender, resuspended in 1.2% NaCl containing antibiotic-
antimycotic solution (100 units Penicillin, 100 mg/mL Streptomy-
cin and 0.25 mg/mL Amphotericin B, Sigma-Aldrich), passed
through a series of stainless steel sieves with sequentially decreasing
pore sizes (450 mm, 180 mm, and 100 mm), and finally retained on
a4 5mm sieve. Control injections were performed using similarly
prepared liver and intestine lysates from age-matched, uninfected
LVG hamsters (Charles River Laboratories).
S. haematobium egg injection
7 to 8 week-old female BALB/c mice were anesthetized with
isoflurane, a midline lower abdominal incision was made, and the
bladder exteriorized. Freshly prepared S. haematobium eggs (3,000
eggs in 50 ml of phosphate-buffered saline, experimental group) or
uninfected hamster liver and intestinal extract (in 50 mlo f
phosphate-buffered saline, control group) was injected submuco-
sally into the anterior aspect of the bladder dome [37]. Abdominal
incisions were then closed with 4-0 Vicryl suture, and the surgical
site was treated once with topical antibiotic ointment.
Micro-ultrasonography
At various time points after bladder wall injection, mice were
anesthetized using vaporized isoflurane and their abdominal walls
were depilated. Transabdominal images of the bladder were then
obtained using a VisualSonics Vevo 770 high-resolution ultra-
sound micro-imaging system with an RMV 704 scanhead
[40 MHz] (Small Animal Imaging Facility, Stanford Center for
Innovation in In-Vivo Imaging).
Bladder histopathologic analysis and collagen
measurement
Mice were sacrificed at serial time points 4 to 99 days after
bladder wall injection, and bladders processed for routine
histology. Morphologic and morphometric analyses were con-
ducted on H&E- and Masson’s Trichrome-stained sections. Total
collagen content was determined from fresh-frozen (270uC)
bladder homogenates using the Sircol Soluble Collagen Assay
Kit (Biocolor, Carrickfergus, United Kingdom) according to the
manufacturer’s instructions. Collagen concentrations were deter-
mined using standard curve analysis. Statistical comparisons were
conducted using Student’s t-test.
IgE ELISA
ELISA measurement of serum IgE was performed using
manufacturer’s instructions (Bethyl Laboratories Mouse IgE
ELISA Quantitation Kit). In brief, coating antibody was aliquoted
into and allowed to bind to microtiter plate wells. Excess antibody
was washed away. Next, blocking solution was added to the wells,
allowed to bind, and excess was washed away. IgE standards and
experimental samples were added to wells, incubated for an hour
at ambient temperature, and washed. HRP detection antibody was
added to each well, incubated, and washed. TMB substrate
solution was then added to each well, developed for 15 minutes at
ambient temperature, and the reactions stopped using Stop
Solution. Absorbance of each well was then read on a plate
reader at 450 nm.
Macrophage-specific immunohistochemistry
Five mm sections from OCT-embedded frozen bladders were
fixed in 10% buffered formalin phosphate, blocked with 10%
horse serum, and incubated overnight at 4uC with a mouse-
specific anti-CD68 antibody (BioLegend, San Diego, CA).
Sections were then processed and developed using an anti-rat
IgG staining kit (Biocare Medical, Concord, CA) according to the
manufacturer’s instructions and counterstained with hematoxylin.
Analysis of bladder-associated leukocytes
Freshly-excised bladders from egg-injected mice were minced
and incubated with agitation in 0.5% heat-inactivated FBS
(Thermo Scientific Hyclone, IL), 20 mM HEPES pH 7, 0.057
Kunitz U/ml DNase I (Sigma-Aldrich), and 1 mg/ml collagenase
B (Roche) in RPMI 1640 medium for 1 hr at 37uC [75]. The
tissue was then passed through a 70 mm nylon cell strainer to
remove undigested tissue and macrocellular debris. After erythro-
cyte lysis (8.02 mg/ml NH4Cl, 0.84 mg/ml NaHCO3, and
0.37 mg/ml EDTA in distilled water), 10
6 cells were treated with
mouse anti-CD16/CD32 (clone 2.4G2, BioLegend, San Diego,
CA) for 10 min and stained with mouse anti–CD3-PE/Cy7 (clone
145-2C11, BioLegend), anti–CD45 (B220)-FITC (clone RA3-6B2,
BioLegend), anti-F4/80-FITC (clone BM8, eBioscience, San
Diego, CA), anti–CD11b-PE (clone M1/70, BioLegend), anti–
Ly-6G(Gr-1)-PECy7 (clone RB6-8C5, eBioscience), anti-CCR3-
FITC (clone RB6-8C5, R&D System, Minneapolis, MN), and/or
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CA) for 30 minutes at 4uC. Cells were analyzed using a BD LSRII
flow cytometer and BD FACSDiva software. Data were analyzed
using FlowJo v7.2.4 (Tree Star, Ashland, OR). Assayed proteins
are listed in Table 1.
Cytokine analysis
Rapidly-excised bladders were placed immediately on ice,
minced in RNAlater solution (Qiagen), and stored at 280uC. For
protein analysis, 50 mg of tissue was sonicated to homogeneity in
1 ml of ice-cold tissue extraction reagent (Biosource, San Diego,
CA) supplemented with 1 mM phenylmethanesulfonyl fluoride.
Clarified bladder extracts and serum samples were assayed using a
mouse 26-plex cytokine kit (Affymetrix, Santa Clara, CA)
according to the manufacturer’s instructions. Samples were read
using a Luminex 200 (Luminex, Austin, TX) with a lower cut off of
100 beads per sample (Human Immune Monitoring Core,
Stanford University). Assayed proteins are listed in Table 1.
RNA purification, cDNA synthesis, and real-time PCR
Regional lymph nodes were harvested and placed in RNAlater
solution (Ambion, Austin, TX), and stored overnight at 4uC, then
at 280uC for long-term storage. RNA was isolated and purified
using RNAqueous -Micro kits (Ambion, Austin, TX) according to
the manufacturer’s instructions. The concentration of RNA was
determined by Quant-iT RNA assay kit (Invitrogen, Eugene, OR)
with the Qubit fluorimeter. The ribosomal RNA band integrity of
each RNA sample was run on an Agilent Bioanalyzer using an
RNA 6000 Nano Labchip. RNA samples with RNA Integrity
Numbers (RIN) of 6 or higher were used for cDNA synthesis and
real-time PCR arrays. cDNA synthesis was performed using the
RT
2 First Strand cDNA Kit (SABiosciences, Frederick, MD).
Real-time PCR was performed in the Mx3005p thermal cycler
(Stratagene) using an RT
2 custom PCR array (SABiosciences) with
RT
2 SYBR Green qPCR Master Mixes (SABiosciences). Cycle
thresholds (Ct) were calculated for each reaction. Using the
comparative Ct method relative gene expression was calculated as
2
(2DDCt), where DCt=Ct (gene of interest) - DCt (normalizer=b-
actin). DDCt was calculated as DCt (egg-injected) - DCt (calibrator).
Data are expressed as mean 6 SD. P values are DCt of egg- versus
control-injected mice. *, P,0.05; **, P,0.01; ***, P,0.005.
Proteins corresponding to assayed genes are listed in Table 1.
Voided spot on paper analysis
Voided spot on paper analysis was performed as previously
described [76,77]. In brief, mice underwent bladder wall injection
with either eggs or control vehicle. One week later, mice were
housed singly and acclimated for one hour in cages lined with filter
paper laid underneath a wire floor bottom. Animals were given ad
libitum access to food and water-soaked sponges placed on wire
cage covers. After 8 hours, each piece of filter paper was
photographed under ultraviolet light to localize voided urine
spots. Total spots were counted for each mouse and the average
number of voids was compared between the egg- and vehicle-
injected mice using two-tailed T-tests. *, P,0.05; **, P,0.01; ***,
P,0.005.
Statistical analysis
Unpaired t tests with Welch’s correction were used for
comparisons between control- and egg-injected groups, and data
were expressed as mean 6 standard deviation. P,0.05 was
considered statistically significant.
Supporting Information
Figure S1 Bladder wall injection induces hematuria and
eosinophiluria. At serial time points after bladder wall injection
with eggs, cytospins were prepared from voided urine (n=2–14/
group), stained with Liu’s stain, and cells identified by morphol-
ogy. This demonstrated significant rates of eosinophiluria (A) and
hematuria (B) in egg-injected mice. In contrast, neither eosinophils
nor erythrocytes were present in voided urine from uninjected and
control-injected mice (data not shown).
(TIF)
Figure S2 Luminex analysis results of total bladder
cytokine expression after bladder wall injection with S.
haematobium eggs.
(TIF)
Table 1. Assayed proteins.
Protein (all Mus musculus) Swiss-Prot Entry #
B220 (Ptprc) Q05C79
CCR3 P51678
CD11b P05555
CD3 epsilon chain P22646
CD68 P31996
eotaxin P48298
F4/80 Q61549
FoxP3 Q99JB6
G-CSF P09920
GM-CSF P01587
Gr-1 (Ly6G) P35461
IFN-c P01580
IL-10 P18893
IL-12 beta subunit P43432
IL-12 alpha subunit P43431
IL-13 P20109
IL-17 Q62386
IL-1a P01582
IL-1b P10749
IL-2 P04351
IL-23 Q9EQ14
IL-3 P01586
IL-4 P07750
IL-5 P04401
IL-6 P08505
IP-10 P17515
KC P12850
MCP-1 P10148
MCP-3 Q03366
MIP-1a P10855
RANTES P30882
Siglec-F Q920G3
TGF-b P04202
TNF-a P06804
VEGF Q00731
doi:10.1371/journal.ppat.1002605.t001
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expression after bladder wall injection with S. haema-
tobium eggs.
(TIF)
Video S1 Micro-ultrasonography of a single represen-
tative animal day 1 post egg injection. Video footage of
micro-ultrasound probe scrolling along the z-axis of the lower
abdomen of an egg-injected mouse demonstrates the presence of a
bright, echogenic (dense) round granuloma impinging on the
upper right side of the urine-filled (black), otherwise ovoid bladder
lumen.
(WMV)
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